ERBB2 and ovarian cancer: Although there is evidence of overexpression of HER2 being associated with a lower sensitivity to platinum-based chemotherapy [41], there was no indication of differential expression in the ovarian cancer cell lines by Western blot, or in the solid tumors by immunohistochemistry that could relate to the sensitivity to carboplatin detected by the clonogenic assay.